Lilly Is Revved Up About Alzheimer's Opportunity
Executive Summary
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.